[Corrections] Correction to Lancet Oncol 2023; 24: 1219–28

January, 01, 2024 | Select Oncology Journal Articles

Douma LH, Lalezari F, van der Noort V, et al. Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study. Lancet Oncol 2023; 24: 1219–28—The appendix of this Article has been corrected as of Oct 27, 2023.

For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –




Sign up for our emails

Trusted insights straight to your inbox and get the latest updates from OncWeekly

Privacy Policy